TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7146263
Drug: Bromazepam, 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam, 18 mg/day
Study: 29101597
Drug: 4.3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.3 g/day n-3 PUFA supplements
Study: 29101597
Drug: 4.3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.3 g/day n-3 PUFA supplements vs Placebo
Study: 26756752
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral prophylaxis (1 g cefmetazole before and every 3 h during surgery plus 1 g oral kanamycin and 750 mg metronidazole twice on the day before surgery)
Study: 26756752
Drug: Parenteral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral prophylaxis alone (1 g cefmetazole before and every 3 h during surgery)
Study: 26756752
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral prophylaxis
Study: 26756752
Drug: Parenteral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral prophylaxis alone
Study: 24670025
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (5 mL)
Study: 24670025
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (5 mL)
Study: 18981485
Drug: MK‐677, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐677, 25 mg, once daily
Study: 15979192
Drug: Sertraline, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, 50 mg/24 h
Study: 15979192
Drug: Ultrasonography and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography and physical therapy (15 sessions of 1 W/cm2 on cervical trigger points)
Study: 12439086
Drug: G(1): 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(1): 8 x 60% T(max) at P(max), 1:2 work:recovery ratio
Study: 12439086
Drug: G(2): 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(2): 8 x 60% T(max) at P(max), recovery at 65% HR(max)
Study: 12439086
Drug: G(3): 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(3): 12 x 30 s at 175% PPO, 4.5-min recovery
Study: 12439086
Drug: G(CON): Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(CON): Control group
Study: 12161053
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day losartan
Study: 12161053
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day fosinopril
Study: 9802743
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg vitamin E for 6 months
Study: 8567766
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa) 0.1 mg s.c.
Study: 668773
Drug: Hydrochlorothiazide 75
Normalized name: triamterene/hydrochlorothiazide 75 mg-50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 75 mg
Study: 668773
Drug: Hydrochlorothiazide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (various doses)
Study: 28389484
Drug: Personal frequency-modulated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personal frequency-modulated systems (FMs) used daily over 10 weeks by 4 patients (intervention care subjects)
Study: 25842726
Drug: Short heating
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short heating time length group (15 min of moxibustion therapy)
Study: 25842726
Drug: Moderate heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate heating time length group (30 min of moxibustion therapy)
Study: 25842726
Drug: Long heating
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long heating time length group (60 min of moxibustion therapy)
Study: 15006188
Drug: APV/RTV 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: APV/RTV 600/100 mg twice daily
Study: 11709566
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (same regimen administered postoperatively)
Study: 9304332
Drug: Intranasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunization with inactivated influenza vaccine (IIV)
Study: 8105790
Drug: Nalmefene augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene augmentation
Study: 3301925
Drug: Intralesional fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional fluorouracil (1 ml of 50 mg/ml)
Study: 3301925
Drug: Control lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lesions (no treatment)
Study: 30870576
Drug: Zoledronate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (4 mg doses, two annual doses)
Study: 21510461
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg) + Metformin (500 mg) bid/tid (n=115)
Study: 21510461
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg) bid/tid (n=114)
Study: 12616661
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch 5% (Lidoderm)
Study: 12616661
Drug: Extended application
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended application of lidocaine patch 5%
Study: 12616661
Drug: Continuous application
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of up to four patches per day
Study: 10623695
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg administered intravenously every month
Study: 6386481
Drug: miniheparin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: miniheparin (2 X 2500 IU daily)‐dihydroergotamine
Study: 6386481
Drug: conventional low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional low‐dose heparin
Study: 26354539
Drug: Beef ingestion
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef ingestion (30 g protein)
Study: 26354539
Drug: Milk ingestion
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk ingestion (30 g protein)
Study: 23301686
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR 10 mg + Naloxone PR 5 mg
Study: 23301686
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR 10 mg
Study: 17926079
Drug: ALA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA and Photofrin fluorescence-guided resection and repetitive photodynamic therapy (PDT)
Study: 17132752
Drug: Lanreotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide treatment
Study: 9819045
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of factor VIII (FVIII) concentrates
Study: 9819045
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of factor IX (FIX) concentrates
Study: 9819045
Drug: Control non-haemophilic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control non-haemophilic patients with heparin prophylaxis
Study: 9819045
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of 50 U/kg of a very high purity clotting factor concentrate
Study: 7659762
Drug: Amphetamine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (oral administration before learning)
Study: 7659762
Drug: Amphetamine (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (intramuscular injection after learning)
Study: 2757893
Drug: 155 mg
Normalized name: lanolin 155 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 155 mg oral tablet of hydroxychloroquine
Study: 2757893
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 155 mg racemic hydroxychloroquine
Study: 334473
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flurbiprofen 3-times daily for 3 weeks
Study: 30647912
Drug: DSF combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSF combined with nutritional copper supplement (DSF-Cu) as an adjuvant to alkylating chemotherapy
Study: 22173608
Drug: PVP combined
Normalized name: PVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP combined with chemotherapy
Study: 15730579
Drug: Anterior subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior subcutaneous transposition
Study: 7420563
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with penicillin-G
Study: 7420563
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment with trimethoprim-sulfamethoxazole
Study: 27377450
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy for Recovery of Self-Esteem (CBGTRS), 12 group sessions
Study: 22267373
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg daily for 5 days
Study: 12685522
Drug: Ritalin LA,
Normalized name: Ritalin LA, (50/50 release) 10 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin LA, Metadate CD, Concerta, Adderall XR (new long-acting formulations of MPH and AMP)
Study: 12685522
Drug: Bolus delivery
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus delivery (BD) and controlled delivery (CD) processes used in drug delivery systems
Study: 1866002
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg dipyridamole and 330 mg acetylsalicylic acid tid
Study: 7102534
Drug: Pindolol, 10
Normalized name: Pindolol, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 10 mg twice a day (n = 7)
Study: 7102534
Drug: Propranolol, median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, median dose 80 mg three times a day (n = 9)
Study: 7102534
Drug: Metoprolol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 150 mg twice a day (n = 8)
Study: 27987040
Drug: Atorvastatin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 60 mg (AT60, n=16)
Study: 27987040
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (AT20, n=14)
Study: 27987040
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with atorvastatin (both doses)
Study: 27009449
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (0.625 mg/0.025 ml)
Study: 27009449
Drug: Conventional indirect
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional indirect laser therapy
Study: 24487616
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment as usual, no exercise)
Study: 17321110
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg, three times weekly for 6 months)
Study: 1505561
Drug: Trimetazidine 6
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 6 mg
Study: 27387325
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m² for six cycles
Study: 24664649
Drug: Nurse-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-initiated treatment
Study: 24664649
Drug: Physician-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-initiated treatment
Study: 20071644
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2 g purified EPA/DHA)
Study: 15902529
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Gram stain, culture, and detection of pneumococcal antigen
Study: 12154113
Drug: Acute ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute ascorbic acid infusion
Study: 9926739
Drug: Ticarcillin/clavulanate 3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin/clavulanate 3.1 g every 6 hours
Study: 9926739
Drug: Imipenem/cilistatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilistatin 500 mg every 6 hours
Study: 8780327
Drug: Sodium channel
Normalized name: Sodium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium channel blocking drugs
Study: 31471833
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse (Tobacco, Alcohol, Psychotropic Drugs)
Study: 28641363
Drug: OXN PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN PR (up to 160/80 mg daily)
Study: 18164644
Drug: Pre-treatment stiffness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment stiffness
Study: 17704850
Drug: Recreational swimming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational swimming combined with asthma education (twice a week for 1 hour over 6 months)
Study: 17704850
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of inhaled corticosteroids (ICS) and short-acting beta2 agonists (salbutamol as needed)
Study: 15078472
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (famciclovir or lamivudine + interferon-alpha-2a)
Study: 11204308
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor (fosinopril) and a statin (pravastatin)
Study: 11204308
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and lipid‐lowering diet
Study: 9741405
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose weekly methotrexate (MTX) therapy (7.5‐12.5 mg/week)
Study: 9768798
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg during sevoflurane anesthesia
Study: 9768798
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg during isoflurane anesthesia
Study: 9768798
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg during propofol anesthesia
Study: 19499738
Drug: Spirulina supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplement (10 grams per day)
Study: 11246298
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin concentration of 70 g/L, maintained between 70 and 90 g/L)
Study: 11246298
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin concentration of 100 g/L, maintained between 100 and 120 g/L)
Study: 31096934
Drug: blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended cognitive behaviour therapy (bCBT)
Study: 21881323
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion in CKD patients (Group C)
Study: 21881323
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion in non-CKD patients (Group D)
Study: 11173169
Drug: Weekly urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly urine testing (n=16)
Study: 11173169
Drug: Monthly urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly urine testing (n=18)
Study: 9430866
Drug: Vancomycin 1000
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1000 mg administered during the last hour of CT haemodialysis
Study: 9430866
Drug: Vancomycin 1000
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1000 mg administered after dialysis
Study: 8238160
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ampicillin or erythromycin)
Study: 2862924
Drug: Clorazepate (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (an anxiolytic)
Study: 28779478
Drug: Calorie-free, tasteless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-free, tasteless control solution
Study: 27236889
Drug: Qingfei Quyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfei Quyu Decoction (QQD), one dose per day for 8 weeks
Study: 24799484
Drug: CVI FU
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI FU (225 mg/m2, 5 days per week)
Study: 24799484
Drug: Capecitabine (825
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (825 mg/m2, twice per day, 5 days per week)
Study: 24799484
Drug: CVI FU
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI FU with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Study: 24799484
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Study: 24799484
Drug: Oxaliplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (50 mg/m2 once per week for 5 weeks)
Study: 17483955
Drug: MRI per
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI per OS with 6% mannitol solution
Study: 17483955
Drug: MRE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRE with nasojejunal intubation and polyethylenglycol solution
Study: 12499885
Drug: Stop group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop group (STOP) - 10 mg prednisolone stopped after day 7 posttransplantation
Study: 12499885
Drug: Tapering group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering group (TAP) - Gradually wean off steroids in 3 to 6 months
Study: 9585276
Drug: Morphine continuous
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg, aiming for a steady-state concentration of 20 ng/mL.
Study: 9585276
Drug: Morphine continuous
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg.
Study: 2664258
Drug: Roxithromycin (RU)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (RU) 300 mg daily for 3 to 7 days
Study: 2664258
Drug: Josamycin (JM)
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (JM) 1200 mg daily for 3 to 7 days
Study: 25585664
Drug: etravirine plus
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine plus an alternative boosted protease inhibitor (other PI group)
Study: 23850111
Drug: Intervention program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention program including physical exercise, recreational activities, and nutritional counseling for 12 weeks (three times weekly)
Study: 21831277
Drug: Monthly health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly health education workshops alone (Group 1)
Study: 21831277
Drug: Monthly health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly health education workshops combined with family orientation through home visits (Group 2)
Study: 17069496
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for 10 sessions per day excluding weekends
Study: 9007680
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (B)
Study: 9007680
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (D)
Study: 22324516
Drug: Levetiracetam extended-release
Normalized name: Levetiracetam Extended-Release Tablets
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam extended-release (XR)
Study: 9241288
Drug: TRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH infusion (400 micrograms)
Study: 31264787
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (GCBT)
Study: 27619827
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg long-acting octreotide once every 4 weeks for 52 weeks
Study: 27619827
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg long-acting octreotide
Study: 22447019
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin therapy
Study: 1463171
Drug: Prewarmed local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prewarmed local anaesthetic solution (37 degrees C)